Open AccessEvaluation of Changes in Citalopram Prescribing Patterns Following a US Food and Drug Administration Alert
Author(s) -
Karyn R. Fabo,
Ann Marie Nye,
Jane P. Gagliardi,
Christopher R. Dennis,
Andrew J. Muzyk
Publication year - 2015
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.14m01657
Subject(s) - citalopram , medicine , torsades de pointes , qt interval , dosing , food and drug administration , emergency medicine , dose , pharmacology , antidepressant , hippocampus
The US Food and Drug Administration (FDA) issued a warning stating that patients older than 60 years are not recommended to receive doses of citalopram exceeding 20 mg daily due to concerns of corrected QT (QTc) prolongation. The purpose of this study is to assess the impact of the FDA warning on prescribing patterns of citalopram in patients 60 years of age and older.